Immune Checkpoint Inhibitors: all 7,569 studies that test it

Page 43 of 76. Open to participants first (2,567), then studies with results posted, then the rest; newest registration first within each.

• PD-1 Inhibitors +Venetoclax+CAG Regimens in R/R T-ALLActive, not recruitingNCT07541755Phase 3
• Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction AdenocarcinomaCompletedNCT07529613Phase 1/2
• Neoadjuvant Low-dose Immunotherapy in Locally Advanced MMR-deficient Colorectal CancerActive, not recruitingNCT07523763Phase 2
• Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)WithdrawnNCT07513324Phase 2
• Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor MalignanciesWithdrawnNCT07511972Phase 2
• Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and EfficacyActive, not recruitingNCT07471815Phase 2
• IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic MelanomaCompletedNCT07436390Not applicable
• Gastrointestinal Microbiome and Response to Immunotherapy in Metastatic Malignant MelanomaActive, not recruitingNCT07428252Not applicable
• A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder CancerWithdrawnNCT07414992Phase 2
• Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS)Active, not recruitingNCT07376317Phase 2
• Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer.WithdrawnNCT07369791Phase 2
• Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24)CompletedNCT07364214Phase 1
• Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung CancerWithdrawnNCT07353957Phase 2
• A Study to Evaluate the PK Similarity of AK112 in Healthy Chinese Male SubjectsActive, not recruitingNCT07340476Phase 1
• Sintilimab Combined With Chemotherapy Induction Therapy Followed by CCRT vs. CCRT for Esophageal Cancer: A Randomized Controlled Phase Ⅲ Clinical StudyActive, not recruitingNCT07306663Phase 3
• Zimberelimab + Domvanalimab in Gastroesophageal AdenocarcinomaWithdrawnNCT07283848Phase 2
• A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and AtezolizumabActive, not recruitingNCT07280377Phase 1/2
• The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective StudyCompletedNCT07272265Not applicable
• Pembrolizumab + MRGOO3 as Neoadjuvant in NPCActive, not recruitingNCT07267338Phase 2
• A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal CancerWithdrawnNCT07223567Phase 2
• Decitabine and Nivolumab in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckWithdrawnNCT07216833Phase 1
• A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer ParticipantsActive, not recruitingNCT07180862Phase 1
• Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT07162883Phase 3
• Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal AdenocarcinomaTerminatedNCT07152821Phase 3
• A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal CancerWithdrawnNCT07137390Phase 1/2
• A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant ChemotherapyActive, not recruitingNCT07136077Phase 2
• Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBCWithdrawnNCT07134556Phase 2
• Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular CarcinomaActive, not recruitingNCT07081633Phase 2
• A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal CancerActive, not recruitingNCT07071714Phase 2
• Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I)SuspendedNCT07057089Phase 2
• TACE With Immune Agents for Angiogenesis in Hepatocellular CarcinomaCompletedNCT07053202Not applicable
• Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell CarcinomaActive, not recruitingNCT07047001Phase 2
• STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1WithdrawnNCT07038915Phase 2
• Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade GliomaActive, not recruitingNCT07031765Phase 1
• Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain MetastasesWithdrawnNCT07011849Phase 2
• A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT07010120Phase 1/2
• A Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung CancerActive, not recruitingNCT07009457Phase 1
• A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung CancerActive, not recruitingNCT07005336Phase 2
• A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCCActive, not recruitingNCT07000149Phase 1
• A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab With Ongoing Durvalumab) Regimen (PRISM) for Resectable/Advanced Hepatocellular CarcinomaWithdrawnNCT06994299Phase 2
• Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.Active, not recruitingNCT06992609Phase 3
• A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung CancerActive, not recruitingNCT06984588Phase 2/3
• A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)SuspendedNCT06959537Phase 1
• A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT06946797Phase 2
• JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLCActive, not recruitingNCT06944470Phase 2
• A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)Active, not recruitingNCT06943833Phase 2
• SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal MetastasesActive, not recruitingNCT06940921Phase 1/2
• A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 ExpressionActive, not recruitingNCT06939452Phase 2
• A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid TumorsActive, not recruitingNCT06932952Phase 1
• Study of ZG005 in Patients With Advanced Solid TumorsActive, not recruitingNCT06927687Phase 2
• Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and ImmunotherapyTerminatedNCT06924606Phase 2
• Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction AdenocarcinomaActive, not recruitingNCT06914687Phase 2
• SCRT+mFOLFOX6+PD-1 Antibody and Targeted Therapy for High-Risk pMMR/MSS Rectal CancerCompletedNCT06908031Phase 2
• PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma PatientsActive, not recruitingNCT06906822Phase 2
• Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung CancerTerminatedNCT06897579Phase 2
• QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract TumorsActive, not recruitingNCT06892925Phase 2
• A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian CancerActive, not recruitingNCT06888921Phase 1/2
• Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With Unresectable Locally Advanced or Postoperative Recurrent Esophageal Squamous Cell CarcinomaActive, not recruitingNCT06885814Phase 2
• Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled StudyCompletedNCT06884670Phase 2
• Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT06866548Early Phase 1
• Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCCSuspendedNCT06860386Phase 2
• Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCCActive, not recruitingNCT06855212Phase 2
• Neoadjuvant Therapy for Locally Advanced Rectal CancerActive, not recruitingNCT06853769Early Phase 1
• A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of RecurrenceTerminatedNCT06851104Phase 2
• A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLCActive, not recruitingNCT06812260Phase 2
• Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal MetastasisActive, not recruitingNCT06809530Phase 1/2
• A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab AloneActive, not recruitingNCT06806852Phase 1
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung CancerCompletedNCT06799286Phase 1
• A Study of Novel Study Interventions and Combinations in Participants With Colorectal CancerActive, not recruitingNCT06792695Phase 2
• Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaTerminatedNCT06790966Phase 3
• IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE CancersActive, not recruitingNCT06790706Phase 2
• Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal CancerActive, not recruitingNCT06784947Phase 2
• BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)Active, not recruitingNCT06773910Phase 2
• Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCCWithdrawnNCT06762808Phase 2
• NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCCActive, not recruitingNCT06762158Not applicable
• Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)Active, not recruitingNCT06760481Phase 1
• A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown PrimaryActive, not recruitingNCT06754501Phase 2
• Low-dose Radiotherapy Combined With Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLCWithdrawnNCT06732258Phase 1
• Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01Active, not recruitingNCT06727565Phase 2
• A Study of AP505 Injection in Patients With Advanced Malignant Solid TumorsActive, not recruitingNCT06723964Phase 1
• A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell CarcinomaTerminatedNCT06716853Phase 1/2
• Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid StructuresWithdrawnNCT06713798Phase 2
• Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal CarcinomaActive, not recruitingNCT06712888Phase 3
• Phase II Clinical Study of Adebrelimab Combined with Apatinib in the Treatment of Locally Advanced Non-small Cell Lung Cancer Patients with Radiation PneumonitisActive, not recruitingNCT06700421Phase 2
• A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)Active, not recruitingNCT06698042Phase 3
• Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)SuspendedNCT06694454Phase 1/2
• Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric CancerActive, not recruitingNCT06693128Phase 2
• Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT06673693Phase 2
• CAPOX Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Neoadjuvant Treatment of Locally Advanced Gastric CancerActive, not recruitingNCT06667050Phase 2
• ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform TrialActive, not recruitingNCT06664879Phase 1/2
• Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung CancerCompletedNCT06648200Phase 2
• AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic CancerActive, not recruitingNCT06646055Phase 1/2
• Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the SkinActive, not recruitingNCT06640530Phase 3
• A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in ChinaActive, not recruitingNCT06640049Phase 2
• PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and EpendymomaSuspendedNCT06639607Phase 1/2
• Agnostic Therapy in Rare Solid TumorsActive, not recruitingNCT06638931Phase 2
• Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)Active, not recruitingNCT06635824Phase 3
• Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)Active, not recruitingNCT06632951Phase 2
• Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung CancerActive, not recruitingNCT06632327Phase 3
• Neoadjuvant Toripalimab Plus Docetaxel and Carboplatin in Patients With Localized TNBC (NeoTOP)Active, not recruitingNCT06618014Phase 2

← Immune Checkpoint Inhibitors overview